IP Library Granted Patent US 12,478,720
Granted Patent B2
US 12,478,720 · App. 17/709,095 · Granted Nov 25, 2025

Polymeric vascular grafts which induce neovascularization with mild to minimal inflammation and promotion of fibrovascular tissue

Inventor: Timothy C. Boire (Houston, TX)
Assignee: VenoStent, Inc.
A61M1/3655A61L31/06A61L31/146
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,720
App. No.
17/709,095
Granted
Nov 25, 2025
Kind
B2
Abstract

The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 400 μm-1200 μm and a pore spacing of about 100 μm to about 750 μm.

Claims (22)

1 . An implantable tissue supporting device comprising:

a biodegradable polymeric scaffold capable of surrounding a tissue, the biodegradable polymeric scaffold includes at least one polymer, the at least one polymer comprising at least one monomer that is crosslinkable, wherein the biodegradable polymeric scaffold is configured to have a melting temperature and be moldable from a first shape to a second shape by an external force when the melting temperature is met or exceeded, wherein the device is mechanically compliant at from about 20° C. to about 50° C., and wherein the biodegradable polymeric scaffold has a pore size of about 800-900 μm and a pore spacing of about 300-450 μm.

2 . The device of claim 1 , wherein the scaffold has a pore size of about 800-850 μm, and a pore spacing of about 325-425 μm.

3 . The device of claim 1 , wherein the scaffold has a pore size of about 815 μm, and a pore spacing of about 326 μm.

4 . The device of claim 1 , wherein the scaffold has a pore size of about 836 μm, and a pore spacing of about 420 μm.

5 . The device of claim 1 , wherein the at least one monomer is allyl functionalized and comprises an allyl carboxylate group.

6 . The device of claim 1 , wherein the at least one monomer comprises ε-caprolactone.

7 . The device claim 1 , wherein the biodegradable polymeric scaffold comprises a plurality of crosslinked polymers, the plurality of crosslinked polymers comprising a poly (ε-caprolactone)-co-(α-allyl carboxylate ε-caprolactone) polymer.

8 . The device of claim 1 , wherein the device forms a seamless and sutureless sheath and has resilient radial expression in a manner that mimics the compliance properties of said tissue.

9 . The device of claim 1 , wherein the biodegradable polymeric scaffold further comprises a shape memory polymer and has a melting temperature at or near 37° C.

10 . The device of claim 1 , wherein the biodegradable polymeric scaffold comprises the at least one monomer that is photocrosslinkable and further comprises at least a second monomer that is not photocrosslinkable.

11 . An implantable tissue supporting device comprising:

a biodegradable polymeric scaffold capable of surrounding a tissue, the biodegradable polymeric scaffold includes at least one polymer, the at least one polymer comprising at least one monomer that is crosslinkable, wherein the biodegradable polymeric scaffold is configured to have a melting temperature and be moldable from a first shape to a second shape by an external force when the melting temperature is met or exceeded, wherein the device is mechanically compliant at from about 20° C. to about 50° C., and wherein the biodegradable polymeric scaffold has a pore size of about 650-800 μm and a pore spacing of about 300-400 μm.

12 . The device of claim 11 , wherein the scaffold has a pore size of about 650-780 μm, and a pore spacing of about 300-350 μm.

13 . The device of claim 11 , wherein the scaffold has a pore size of about 680 μm, and a pore spacing of about 328 μm.

14 . The device of claim 11 , wherein the scaffold has a pore size of about 777 μm, and a pore spacing of about 310 μm.

15 . The device of claim 11 , wherein the at least one monomer is allyl functionalized and comprises an allyl carboxylate group.

16 . The device of claim 11 , wherein the at least one monomer comprises ε-caprolactone.

17 . The device claim 11 , wherein the biodegradable polymeric scaffold comprises a plurality of crosslinked polymers, the plurality of crosslinked includes comprising a poly (ε-caprolactone)-co-(α-allyl carboxylate ε-caprolactone) polymer.

18 . The device of claim 11 , wherein the device forms a seamless and sutureless sheath and has resilient radial expression in a manner that mimics the compliance properties of said tissue.

19 . The device of claim 11 , wherein the biodegradable polymeric scaffold further comprises a shape memory polymer having a melting temperature at or near 37° C.

20 . The device of claim 11 , wherein the biodegradable polymeric scaffold comprises the at least one monomer that is photocrosslinkable and further comprises at least a second monomer that is not photocrosslinkable.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: BOIRE, TIMOTHY C.
To: VENOSTENT, INC.
Reel/Frame 060820/0554 →
Continuity (3)
Continuation In Part 16824674 · Mar 19, 2020
Provisional Application 62820785 · Mar 19, 2019
Related Publication 20220218882A1 · Jul 14, 2022
References Cited (2)
US 11305039B2 · Boire · 2022 [cited by examiner]
Woodward et al, Porous PCL-PCLA Semi-IPNs as Superior, Defect-Specific Scaffolds with Potential for Cranial Bone Defect Repair, Biomacromolecules: 16(12), 4075-4083. (Year: 2017). [cited by examiner]